



# Some facts about PARI and its partnering for pharmaceutical companies


We offer optimized nebulizers enabling advanced aerosol therapies for the benefit of patients.



**Founded in 1906**, privately owned company



**670+** employees worldwide, **120** in the USA



**Committed team** with a strategic orientation to partnering



**Track record** in development and commercialization of drug-device combination products



**Multiple manufacturing sites** with extensive manufacturing & supply capabilities



We design, develop and manufacture **optimized eFlow® Technology nebulizers** in cooperation with and for our partners from the pharmaceutical industry. Therefore, we contribute to **advanced drug-device combination products** that bring **relieve for patients** with mostly severe lung diseases.



**12+** More than a dozen **active (license) partnerships** – from preclinical to commercial phase



**eFlow® Technology platform** suitable for a wide range of medications and patient populations



PARI provides **comprehensive analytical support for nebulizer customization and aerosol characterization** in all (non) clinical phases



Platform approach enables **short development times** for optimized nebulizers



Vibrating membrane nebulizers for fast and **efficient nebulization**



The **aerosol droplet size can be tailored** to specific medications and the needs of the respective patient population



**Laboratories are** fully accredited to the **highest quality** standards (GMP)

You want to learn more? Please visit [www.pari.com/eflow-partnering](http://www.pari.com/eflow-partnering) and get in touch with us!